Kinomics-structural biology and chemogenomics of kinase inhibitors and targets

被引:156
作者
Vieth, M [1 ]
Higgs, RE [1 ]
Robertson, DH [1 ]
Shapiro, M [1 ]
Gragg, EA [1 ]
Hemmerle, H [1 ]
机构
[1] Eli Lilly & Co, Lilly Res Labs, Lilly Corp Ctr, Indianapolis, IN 46285 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS | 2004年 / 1697卷 / 1-2期
关键词
protein kinase; ATP binding site; chemogenomics; kinase similarity; binding fingerprint; SAR similarity;
D O I
10.1016/j.bbapap.2003.11.028
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Classifying kinases based entirely on small molecule selectivity data is a new approach to drug discovery that allows scientists to understand relationships between targets. This approach combines the understanding of small molecules and targets, and thereby assists the researcher in finding new targets for existing molecules or understanding selectivity and polypharmacology of molecules in related targets. Currently, structural information is available for relatively few of the protein kinases encoded in the human genome (7% of the estimated 518); however, even the current knowledge base, when paired with structure-based design techniques, can assist in the identification and optimization of novel kinase inhibitors across the entire protein class. Chemogenomics attempts to combine genomic data, structural biological data, classical dendrograms, and selectivity data to explore, define, and classify the medicinally relevant kinase space. Exploitation of this information in the discovery of kinase inhibitors defines practical kinase chemogenomics (kinomics). In this paper, we review the available information on kinase targets and their inhibitors, and present the relationships between the various classification schema for kinase space. In particular, we present the first dendrogram of kinases based entirely on small molecule selectivity data. We find that the selectivity dendrogram differs from sequence-based clustering mostly in the higher-level groupings of the smaller clusters, and remains very comparable for closely homologous targets. Highly homologous kinases are, on average, inhibited comparably by small molecules. This observation, although intuitive, is very important to the process of target selection, as one would expect difficulty in achieving inhibitor selectivity for kinases that share high sequence identity. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:243 / 257
页数:15
相关论文
共 107 条
  • [1] 7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d] pyrimidines -: Potent inhibitors of the tyrosine kinase c-Src
    Altmann, E
    Missbach, M
    Green, J
    Susa, M
    Wagenknecht, HA
    Widler, L
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (06) : 853 - 856
  • [2] Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I
    Arnold, LD
    Calderwood, DJ
    Dixon, RW
    Johnston, DN
    Kamens, JS
    Munschauer, R
    Rafferty, P
    Ratnofsky, SE
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (19) : 2167 - 2170
  • [3] A protein kinase inhibitor, fasudil (AT-877): A novel approach to signal transduction therapy
    Asano, T
    Ikegaki, I
    Satoh, S
    Seto, M
    Sasaki, Y
    [J]. CARDIOVASCULAR DRUG REVIEWS, 1998, 16 (01): : 76 - 87
  • [4] Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
    Azam, M
    Latek, RR
    Daley, GQ
    [J]. CELL, 2003, 112 (06) : 831 - 843
  • [5] PROTEIN DATA BANK - COMPUTER-BASED ARCHIVAL FILE FOR MACROMOLECULAR STRUCTURES
    BERNSTEIN, FC
    KOETZLE, TF
    WILLIAMS, GJB
    MEYER, EF
    BRICE, MD
    RODGERS, JR
    KENNARD, O
    SHIMANOUCHI, T
    TASUMI, M
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1977, 112 (03) : 535 - 542
  • [6] New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
    Bold, G
    Altmann, KH
    Frei, J
    Lang, M
    Manley, PW
    Traxler, P
    Wietfeld, B
    Brüggen, J
    Buchdunger, E
    Cozens, R
    Ferrari, S
    Furet, P
    Hofmann, F
    Martiny-Baron, G
    Mestan, J
    Rösel, J
    Sills, M
    Stover, D
    Acemoglu, F
    Boss, E
    Emmenegger, R
    Lässer, L
    Masso, E
    Roth, R
    Schlachter, C
    Vetterli, W
    Wyss, D
    Wood, JM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (12) : 2310 - 2323
  • [7] Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity
    Boschelli, DH
    Ye, F
    Wang, YD
    Dutia, M
    Johnson, SL
    Wu, BQ
    Miller, K
    Powell, DW
    Yaczko, D
    Young, M
    Tischler, M
    Arndt, K
    Discafani, C
    Etienne, C
    Gibbons, J
    Grod, J
    Lucas, J
    Weber, JM
    Boschelli, F
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (23) : 3965 - 3977
  • [8] Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines:: Identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors
    Boschelli, DH
    Wu, ZP
    Klutchko, SR
    Showalter, HDH
    Hamby, JM
    Lu, GH
    Major, TC
    Dahring, TK
    Batley, B
    Panek, RL
    Keiser, J
    Hartl, BG
    Kraker, AJ
    Klohs, WD
    Roberts, BJ
    Patmore, S
    Elliott, WL
    Steinkampf, R
    Bradford, LA
    Hallak, H
    Doherty, AM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (22) : 4365 - 4377
  • [9] Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles
    Boschelli, DH
    Wang, YD
    Ye, F
    Wu, BQ
    Zhang, N
    Dutia, M
    Powell, DW
    Wissner, A
    Arndt, K
    Weber, JM
    Boschelli, F
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (05) : 822 - 833
  • [10] PROTEIN-KINASES - STRUCTURE AND FUNCTION
    BOSSEMEYER, D
    [J]. FEBS LETTERS, 1995, 369 (01) : 57 - 61